Business
Press Release Dec 16 2025
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 16, 2025, titled "Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma".
About this update from Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 16, 2025, titled "Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma". View Attachment
View stock analysis, news, and events for Glenmark Pharmaceuticals Limited